Back to top
more

BridgeBio Pharma (BBIO)

(Delayed Data from NSDQ)

$27.05 USD

27.05
885,929

+0.35 (1.31%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $27.05 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Does BridgeBio Pharma (BBIO) Have the Potential to Rally 67.36% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 67.4% upside potential for BridgeBio Pharma (BBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.16% and 84.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Amphastar Pharmaceuticals (AMPH) Q3 Earnings Expected to Decline

by Zacks Equity Research

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will BridgeBio Pharma (BBIO) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 11.96% and 146.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

BridgeBio Pharma (BBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates

by Zacks Equity Research

Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.

BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor

by Zacks Equity Research

BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.

BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Personalis (PSNL) delivered earnings and revenue surprises of -10.53% and 2.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, BridgeBio Pharma (BBIO) closed at $8.66, marking a -1.25% move from the previous day.

BridgeBio Pharma (BBIO) Gains As Market Dips: What You Should Know

by Zacks Equity Research

BridgeBio Pharma (BBIO) closed at $10.02 in the latest trading session, marking a +0.1% move from the prior day.

BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio (BBIO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.

BridgeBio Pharma (BBIO) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

BridgeBio Pharma (BBIO) closed the most recent trading day at $8.54, moving -1.61% from the previous trading session.

BridgeBio Pharma (BBIO) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

BridgeBio Pharma (BBIO) closed the most recent trading day at $9.99, moving +1.83% from the previous trading session.

BridgeBio Pharma (BBIO) Gains But Lags Market: What You Should Know

by Zacks Equity Research

BridgeBio Pharma (BBIO) closed the most recent trading day at $9.04, moving +1.01% from the previous trading session.

BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study

by Zacks Equity Research

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study

by Zacks Equity Research

BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.

BridgeBio Pharma (BBIO) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

BridgeBio Pharma (BBIO) closed the most recent trading day at $14.65, moving -1.81% from the previous trading session.

BridgeBio Pharma (BBIO) Moves 14.6% Higher: Will This Strength Last?

by Zacks Equity Research

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.